ALK and non-small cell lung carcinoma: The quality of studies was evaluated using tools such as the Newcastle-Ottawa Scale (NOS) and the Cochrane risk-of-bias tool.<h4>Results</h4>A total of 30 studies involving 2737 patients with ALK-positive NSCLC were included.